Coventry-based Skyfarer has partnered with University Hospitals Coventry and Warwickshire NHS Trust to test drone delivery of radioactive medicines, potentially reducing transport time significantly.

Osivax has dosed the first participant in a Phase 2a clinical trial evaluating OVX836 as a booster for its broad-spectrum influenza vaccine candidate.

Research from the Medical University of South Carolina indicates that single-dose IVIG therapy (2g/kg) may be sufficient for clearing BK viral load in nephropathy patients, potentially reducing overall treatment costs.

A study by the Medical University of South Carolina demonstrates that home administration of long-acting injectable antiretroviral therapy (ART) for HIV patients is as safe and effective as clinic-based administration.

The Clear Roads research program unites transportation experts nationwide to advance winter maintenance strategies.

The EMA's CHMP has recommended not renewing the marketing authorization for Translarna (ataluren) for Duchenne muscular dystrophy patients with nonsense mutations.

Dr. Jennifer Jao of Northwestern University will co-chair the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) Network.

Northeastern University researchers have formally petitioned the FDA to revoke approval of Humacyte's artificial blood vessel Symvess, citing deficient clinical trial data and safety concerns.

New research from Johns Hopkins University reveals that semaglutide (Ozempic, Wegovy) is associated with a 32% increased relative risk of nonarteritic anterior ischemic optic neuropathy, a potentially blinding eye condition.

Research published in the journal Heart reveals that individuals who walk at a brisk pace (over 4 mph) have a 43% lower risk of developing abnormal heart rhythms compared to slower walkers.

The University Hospitals of North Midlands NHS Trust (UHNM) has been acknowledged as a top recruiter of patients for two significant national clinical trials on stroke treatment, ATTEST 2 and OPTIMAS, with findings published in the Lancet and presented at the World Stroke Congress 2024.

A novel implantable biobattery developed by researchers at University of Wollongong and Jilin University reduced tumor size from over 1,000 mm³ to just 4 mm³ in 14 days, achieving a 99.6% reduction.

Precision medicine in oncology has evolved from early hormone-based treatments to sophisticated molecular targeting, revolutionizing treatment approaches for diseases like breast cancer and CML.

A recent study in _Nature Medicine_ found that 43% of FDA-authorized AI medical devices lack publicly available clinical validation data, raising concerns about their effectiveness.

Agios Pharmaceuticals has completed enrollment for the Phase 3 RISE UP study evaluating mitapivat in sickle cell disease patients aged 16 and older.

Hockey players who suffered three or more concussions had twice the risk of depression symptoms compared to those without concussion history, according to new Swedish research.

Luspatercept's approval offers an effective and well-tolerated first-line treatment for anemia in lower-risk myelodysplastic syndrome (MDS) patients without prior ESA use.

Caribou Biosciences has received FDA clearance for its IND application for CB-010, an allogeneic anti-CD19 CAR-T cell therapy, to treat lupus nephritis and extrarenal lupus. The GALLOP Phase 1 clinical trial is set to begin by the end of 2024, following encouraging results from the ANTLER trial for B cell non-Hodgkin lymphoma.

This article reviews the efficacy and safety of fedratinib in treating myelofibrosis, based on clinical trial data and real-world evidence. It highlights the drug's impact on spleen volume response, symptom improvement, and adverse effects, including gastrointestinal issues and hematologic toxicities.

A 26-year-old bone cancer survivor has received the first known transplant of sperm-producing stem cells preserved from his childhood, marking a significant advancement in fertility preservation for pediatric cancer patients.